MORGAN CECIL: Open Payments
NPI 1912653437 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,174 in 113 payments from 13 companies in 2025. Trend: 2023 $1,612 · 2024 $2,280 · 2025 $2,174
Food & beverage: $2,174
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $600 |
| Janssen Biotech, Inc. | 24 | $547 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $197 |
| GENZYME CORPORATION | 4 | $125 |
| Gilead Sciences, Inc. | 5 | $114 |
| Madrigal Pharmaceuticals | 5 | $112 |
| Lilly USA, LLC | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| Novo Nordisk Inc | 2 | $39 |
Products named: TREMFYA, RINVOQ, DUPIXENT, XIFAXAN, ENTYVIO, REZDIFFRA, OMVOH, CREON.
Industry payments across KY — which companies pay providers there.
